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Abstract
Background: Active case detection through mass community screening is a major control strategy against human
African trypanosomiasis (HAT, sleeping sickness) caused by T. brucei gambiense. However, its impact can be limited
by incomplete attendance at screening sessions (screening coverage) and diagnostic inaccuracy.
Methods: We developed a model-based approach to estimate the true prevalence and the fraction of cases
detected during mass screening, based on observed prevalence, and adjusting for incomplete screening coverage
and inaccuracy of diagnostic algorithms for screening, confirmation and HAT stage classification. We applied the
model to data from three Médecins Sans Frontières projects in Uganda (Adjumani, Arua-Yumbe) and Southern
Sudan (Kiri).
Results: We analysed 604 screening sessions, targeting about 710 000 people. Cases were about twice as likely to
attend screening as non-cases, with no apparent difference by stage. Past incidence, population size and repeat
screening rounds were strongly associated with observed prevalence. The estimated true prevalence was 0.46% to 0.90%
in Kiri depending on the analysis approach, compared to an observed prevalence of 0.45%; 0.59% to 0.87% in Adjumani,
compared to 0.92%; and 0.18% to 0.24% in Arua-Yumbe, compared to 0.21%. The true ratio of stage 1 to stage 2 cases
was around two-three times higher than that observed, due to stage misclassification. The estimated detected fraction
was between 42.2% and 84.0% in Kiri, 52.5% to 79.9% in Adjumani and 59.3% to 88.0% in Arua-Yumbe.
Conclusions: In these well-resourced projects, a moderate to high fraction of cases appeared to be detected
through mass screening. True prevalence differed little from observed prevalence for monitoring purposes. We
discuss some limitations to our model that illustrate several difficulties of estimating the unseen burden of neglected
tropical diseases.
Keywords: Trypanosomiasis, Gambiense, Sleeping sickness, Case detection, Screening, Coverage, Prevalence,
Uganda, Sudan, Mathematical model
Background
Human African trypanosomiasis (HAT, sleeping sickness)
due to Trypanosoma brucei gambiense is a neglected,
tsetse-fly borne parasitic disease that affects mainly
remote and crisis-affected populations of sub-Saharan
Africa [1]. Disease begins in amildly symptomatic, haemo-
lymphatic stage (stage 1) and within about 1–2 years
progresses to the meningo-encephalitic stage 2, which is
fatal unless treated and can leave sequelae [2,3].
Active case detection has been a mainstay intervention
to control HAT since the 1920s [4]. It consists of cross-
sectional mass screenings, whereby entire communities
(usually villages or urban neighbourhoods) are targeted
for testing. The screening test is usually the Card Agglu-
tination Test for Trypanosomiasis (CATT), though
palpation of lymph nodes in the neck is also often per-
formed (enlarged lymph nodes are a prominent sign of
HAT). The confirmation and staging components of the
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complex diagnostic algorithm [5] are carried out either
on site or at a fixed HAT treatment centre, depending
on proximity and ease of patient transport. Staging
and treatment are often done at the treatment centre,
but stage 1 cases are increasingly treated at the com-
munity level.
Active case detection prevents disease progression to
stage 2 through early treatment irrespective of symp-
toms; reduces mortality of stage 2 cases; decreases trans-
mission intensity by reducing the infectious pool
(humans are thought to be the main ecological reservoir
[1]); creates community awareness; and generates an
estimate of infection prevalence, the key indicator of
HAT burden. Mass screening is empirically associated
with reduction in transmission in various settings [6-8],
and its decline in the post-colonial era is heavily impli-
cated in the resurgence of HAT in the 1980s and 1990s
[9-11].
Active case detection may be indispensible for HAT
elimination [6,12]. However, attendance at screening
sessions is often low, and diagnostic sensitivity is imper-
fect [13], limiting its impact. Furthermore, false positives
due to imperfect specificity confound prevalence esti-
mates. Here, we use modelling to estimate the fraction
of cases detected during mass screening (henceforth
referred to as the detected fraction) and the true infec-
tion prevalence based on data from three Médecins Sans
Frontières (MSF) projects in Uganda and Southern
Sudan. Estimates of the detected fraction and true preva-
lence are critical for evaluating the true impact of con-
trol programmes and measuring the unseen burden of
this neglected tropical disease.
Methods
Data sources
We assembled aggregate data from screening sessions
conducted in the Kiri (Kajo-Keji county, Southern
Sudan), Adjumani and Arua-Yumbe (north west Uganda)
MSF projects, previously described [14-17]. Data include
village population size (estimated through census by
home visitors), numbers screened and cases detected by
stage. We excluded sessions that yielded zero prevalence
in villages where no cases were detected throughout the
project duration. The study was approved by the Ethics
Committee of the London School of Hygiene and Trop-
ical Medicine.
Conceptual framework
Model states and parameters are listed in Table 1. Let
screening coverage c be the number of people screened
divided by the total village population N; detected
fraction the number of truly positive stage 1 or stage 2
cases detected (S1,TP, S2,TP) out of all cases prevalent
(S1, S2); and observed prevalence the number of cases diag-
nosed (including false positives) in either stage (S1,TP + S1,
FP, S2,TP + S2,FP), divided by the number of people screened
(cN).
We hypothesized that the relative probability ρ of
attending screening during a session is higher for cases
than for non-cases. Accordingly, as screening coverage
decreases, the selection bias favouring cases should in-
crease, yielding a higher observed prevalence at coverage
c (for c < 1), compared to the prevalence measurable
if c = 1. We can thus define a coverage-dependent
ratio of observed prevalence for any screening cover-
age < 1, compared to observed prevalence when everyone
is screened:
βc ¼
Sobs;c
cN
h i
c<1
Sobs;c
cN
h i
c¼1
ð1Þ
Under this hypothesis, βc should increase exponen-
tially as screening coverage decreases.
In addition, observed prevalence is biased upward by
false positive tests (incomplete diagnostic specificity),
and downward by false negatives (incomplete sensitivity),
while the number of stage 1 and stage 2 cases is biased
by stage misclassification (Figure 1).
In this paper we develop a static, stochastic mathem-
atical model to predict the relationship between
observed prevalence and true prevalence given a specific
relative probability ρ of attending a screening session
among cases compared to non-cases, which is a para-
meter we can estimate from field data. This model
enabled us to estimate true prevalence and therefore
the detected fraction. The different steps in the imple-
mentation of the model are outlined in Table 2, and
described below.
Description of the mathematical model
The model predicts the number of stage 1 and stage 2
observed cases (S1,obs and S2,obs) and the true cases
among these (S1,TP and S2,TP), based on a set of input
parameters, including village population N, true number
of prevalent cases S1 and S2, screening coverage c, rela-
tive risk of attending screening among cases versus non-
cases ρ, and accuracy (sensitivity, specificity, probabilities
of correct stage 1 and 2 classification) of the diagnostic
algorithm, as estimated in previous work [13].
Because the number of prevalent cases in a village is
often very small and in order to incorporate uncertainty
in several parameters, the model was implemented sto-
chastically. Accordingly, individuals in the population
have a given probability of experiencing certain events
(e.g. attending screening, being detected if positive);
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chance determines whether the event occurs. The sto-
chastic variation is then examined over a large number
of iterations of the model: best estimates and confidence
intervals are generated from the distribution of predicted
values. Furthermore, during each iteration fresh random
values of certain parameters (e.g. diagnostic accuracy)
are drawn from their distributions.
Cases and non-cases screened
The model firstly predicts the number of cases and non-
cases screened. If coverage = 1, everyone is screened. If
coverage < 1, the situation is akin to sampling without
replacement, with sample size = people screened (cN).
The probabilities that the ith person screened will be a
stage 1 case, stage 2 case or non-case are the product of
Table 1 Model parameters
Parameter Symbol Values Source/Notes
Village population size N Variable Data
Screening coverage (%) c Variable Data
Relative probability of attending
screening (cases versus non-cases)
ρ Project Estimate
(95% percentiles)
Prediction of step 1 of model. Random values for
each iteration sampled from squared deviance
distributions of ρ estimates.
Kiri 1.6 (0.7-12.8)
Adjumani 2.5 (1.2-36.6)
Arua-Yumbe 1.9 (0.9-4.0)
Probability that the next person
screened is S1 or S2
pS1, pS2 from 0 to 1 Updated after each i
th person screened.
See Equations 4 and 5.
Ratio of observed prevalence at
coverage c to observed prevalence
at coverage = 100%.
βc Computed for various values of c,
and for each MSF project as a whole.
Data and model predictions. See Equation 1
and text.
Diagnostic accuracy Algorithm Mode (range) Random values sampled from the likelihood
distributions generated by Checchi et al. [13] based
on a probabilistic decision model (one random
value generated for each iteration).
Values for the new Kiri algorithm apply to all screenings
conducted since March 2005 (n = 17).
Diagnostic sensitivity in stage 1 (%) σ1 Kiri (old) 98.0 (83.1-99.5)
Kiri (new) 57.4 (41.2-78.2)
Adjumani 97.9 (74.1-99.2)
Arua-Yumbe 96.5 (74.6-98.8)
Diagnostic sensitivity in stage 2 (%) σ2 Kiri (old) 98.0 (83.5-99.6)
Kiri (new) 67.5 (53.6-84.0)
Adjumani 97.5 (75.1-99.4)
Arua-Yumbe 97.7 (75.0-99.3)
Diagnostic specificity (%) φ Kiri (old) 100.0 (99.8- 100.0)
Kiri (new) 100.0 (99.95-100.0)
Adjumani 100.0 (99.8-100.0)
Arua-Yumbe 100.0 (99.8-100.0)
Probability of being correctly
classified into stage 1 (%)
σ*1 Kiri (old) 67.7 (38.5-86.8)
Kiri (new) 66.0 (39.0-87.2)
Adjumani 70.4 (39.1-88.6)
Arua-Yumbe 66.1 (39.2-88.5)
Probability of being correctly
classified into stage 2 (%)
σ*2 Kiri (old) 94.7 (82.1-98.6)
Kiri (new) 95.1 (81.4-98.4)
Adjumani 94.0 (78.7-98.2)
Arua-Yumbe 93.1 (78.7-98.2)
Probability that a false positive case
will be classified into stage 1 (%)
ω Kiri (old) 0.0 Based on the algorithms used in these projects,
false positives can only be classified as stage 2 [13].
Kiri (new) 0.0
Adjumani 0.0
Arua-Yumbe 0.0
Binary dummy variables δ[. . .] 0 or 1 Denote occurrence of event in a
given individual.
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ρ and the relative proportions of each type of patient
in the remaining unscreened population, which change
and thus must be updated after each person is screened.
Accordingly, the number of cases predicted to be
screened over the entire screening session is computed
as follows:
S1;sc;pred ¼
XcN
i¼1
δ1;sc;i;whereδ1;sc;i ¼
1;
0;
Uniform 0; 1½ ≤pS1;i
Uniform 0; 1½  > pS1;i

ð2Þ
S2;sc;pred ¼
XcN
i¼1
δ2;sc;i;whereδ2;sc;i ¼
1;
0;
Uniform 0; 1½ ≤pS2;i
Uniform 0; 1½  > pS2;i

ð3Þ
In the above equations, random numbers between 0
and 1 are sampled from a uniform distribution to deter-
mine whether an event occurs. The probabilities that
the next person screened is a stage 1 or stage 2 case are,
respectively:
The number of predicted non-cases screened is the
total sample cN minus cases screened:
Hsc;pred ¼ cN  S1;sc;pred  S2;sc;pred ð6Þ
In cases where c > 1 (as can occur if people from sur-
rounding villages also attend the screening session), we
assumed that the entire village population was screened,
i.e. c = 1 for the village in question; additional persons
screened from outside the village are ignored in the
model, as they do not contribute to the prevalence pool
(and thus the detected fraction) within the village in
question. MSF datasets specify the origin of cases
detected and only cases from the village screened were
considered in our analysis. However, when computing
observed prevalence, all persons screened (including
those from outside the village) were considered in the
denominator, as MSF data do not contain the origin of
persons screened. In both Uganda and Sudan projects,
observed prevalence was also calculated in this way.
pS1;i ¼
ρ S1 
Xi1
j¼1δ1;sc;j
 
ρ S1 
Xi1
j¼1δ1;sc;j
 
þ ρ S2 
Xi1
j¼1δ2;sc;j
 
þ N  i 1ð Þ 
Xi1
j¼1δ1;sc;j 
Xi1
j¼1δ2;sc;j
ð4Þ
pS2;i ¼
ρ S2 
Xi1
j¼1δ2;sc;j
 
ρ S1 
Xi1
j¼1δ1;sc;j
 
þ ρ S2 
Xi1
j¼1δ2;sc;j
 
þ N  i 1ð Þ 
Xi1
j¼1δ1;sc;j 
Xi1
j¼1δ2;sc;j
ð5Þ
Figure 1 Illustration of the relationship between true and observed prevalence during mass screening.
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True cases detected
The number of true cases detected among those
screened is given by the binomial probability of detec-
tion conditional on being screened (diagnostic sensitivity
σ), applied to each case screened:
S1;TP;pred ¼ Bin S1;sc;pred; σ1
  ð7Þ
S2;TP;pred ¼ Bin S2;sc;pred; σ2
  ð8Þ
However, some cases detected are misclassified in the
wrong stage:
S1;TP;mis;pred ¼ Bin S1;TP;pred; 1 σ1
  ð9Þ
S2;TP;mis;pred ¼ Bin S2;TP;pred; 1 σ2
  ð10Þ
False positive cases
Out of non-cases screened, some are classified as false
positives due to imperfect specificity:
SFP;pred ¼ Bin Hsc;pred; 1 φ
  ð11Þ
For completeness, we note that some false positives
may be classified as stage 1, based on the relative
proportion ω of stage 1 s among all false positives,
which is highly dependent on the diagnostic algorithm
being used:
S1;FP;pred ¼ Bin SFP;pred;ω
  ð12Þ
All other false positives are classified as stage 2:
S2;FP;pred ¼ SFP;pred  S1;FP;pred ð13Þ
In practice, ω was estimated at zero in the MSF pro-
jects we analysed [13].
Predicted observed prevalence
The predicted numbers of cases observed include true
and false positives, with some stage misclassification:
S1;obs;pred ¼ S1;TP;pred  S1;TP;mis;pred þ S2;TP;mis;pred
þ S1;FP;pred ð14Þ
Table 2 Steps in the implementation of the model
Step 1 Step 2
Purpose Estimate ρ (relative probability of attending screening among
cases versus non-cases)
Estimate the true prevalence and the detected fraction
Geographical resolution Each MSF project Each screening session (results then totalled over
each project)
Model inputs Project-specific diagnostic accuracy parameters Diagnostic accuracy parameters
N = 10 000, S1 =Uniform [1–50] and S2 =Uniform [1–50]
(hypothetical values)
Observed N, c, S1,obs and S2,obs for
the screening session
Observed βc (ratio of observed prevalence at coverage c to
observed prevalence at coverage= 100%) for four coverage
strata (5-24%, 25-44%, 45-64% and 65-84%)
ρ values estimated in Step 1 for
each MSF project, sampled from
their deviance distribution
Observed c values sampled from within each coverage
stratum and for each project
Various candidate sets of S1 and S2
(true prevalent cases)
Various candidate ρ values
Model predicted outputs βc for the same coverage strata (5-24%, 25-44%, 45-64%
and 65-84%)
Number of observed cases
(S1,pred and S2,pred)
Number of true positive cases among
those observed (S1,TP,pred and S2,TP,pred)
Number of iterations 10 000 for each project and for each candidate ρ value 10 000 for each screening session and
for each candidate set of S1 and S2
Fitting procedure Predictions fitted against observed βc for the same
coverage strata.
Predictions fitted against actual observed
cases in screening session (S1,obs and S2,obs).
Observed βc estimated based on a statistical model of
field data.
S1 and S2 candidate sets resulting in
best-fitting S1,pred and S2,pred adopted as
maximum likelihood estimates of true
prevalence. Joint likelihood distribution
informs confidence intervals.
Candidate ρ value resulting in best-fitting βc adopted as
point estimate of ρ. Confidence interval based on squared
deviance distribution.
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S2;obs;pred ¼ S2;TP;pred  S2;TP;mis;pred þ S1;TP;mis;pred
þ S2;FP;pred ð15Þ
Sobs;pred ¼ S1;obs;pred þ S2;obs;pred ð16Þ
The model's predictions can be plugged into Equation
1 so as to predict βc for any screening coverage level,
compared to 100% coverage.
Step 1: Estimation of the relative probability of attending
screening (ρ)
Estimation of observed to true prevalence ratio (βc) based
on field data
We estimated the actual βc within each MSF project and
for four screening coverage strata (5-24%, 25-44%, 45-64%
and 65-84%), compared to coverage 85-115% as the reference
stratum (while this reference stratum should theoretic-
ally consist only of screening sessions with c = 100%, in
practice very few screening sessions achieved exactly
this coverage, and we therefore adopted a wider range
assuming that it was practically equivalent to 100%).
We estimated βc based on screening data and a statis-
tical model of the association between screening cover-
age and observed prevalence.
As observed prevalence distributions featured an
excess of zeroes and were over-dispersed, a hurdle
model [18,19] was used to estimate βc, consisting of (i) a
first complementary log-log binomial component that
models the probability of a non-zero prevalence, and
(ii) a second negative binomial component (offset by the
natural log of the number of people screened) that mod-
els the probability of a given discrete number of cases,
conditional on prevalence being non-zero (i.e. on the
first “hurdle” of zero having been crossed). This model
provided a good fit to the data (results not shown).
In addition to screening coverage, all potential con-
founding variables available from the data (screening
round [first versus subsequent], village population size,
observed incidence rate in the six months before the
mass screening, and project) were included in the hurdle
model. Coefficient standard errors were adjusted for
clustering due to repeated screening sessions within
individual villages (to do this, "village" was set as the
cluster variable).
So as to verify whether ρ differs in stage 2 versus stage
1 cases, we also stratified the hurdle model by stage, and
modelled the association between screening coverage
and the proportion of stage 2 diagnoses using an alterna-
tive group logit regression. Both these analyses (omitted
for brevity) suggested no significant difference in βc
according to stage; we thus assumed that ρ is equal for
stage 1 and stage 2.
Estimation of ρ for each MSF project
We implemented the stochastic model described above
to predict βc for various coverage values and for each
MSF project, as a function of different values of ρ. For
each candidate value of ρ in a large plausible range,
we examined the distribution of βc generated from
10 000 runs of the stochastic model, and adopted the
value of ρ that generated predicted values of βc that best
fit those estimated for each site from the available data,
i.e. the hurdle model. The value of ρ yielding the best fit-
ting value of βc was selected by minimizing the squared
deviation of the predicted βc compared to the actual βc,
with actual values sampled from the uncertainty distri-
bution provided by the coefficients of the hurdle model
(Table 1). The model was run using the diagnostic
accuracy parameters specific to each project, sampled
from their uncertainty distributions as computed in
prior work, and input values of N= 10 000, S1 =Uniform
[1–50] and S2 =Uniform [1–50] (the results were
insensitive to input values of N, S1 and S2). The coverage
values at which we predicted βc were also randomly
selected from the distribution of screening session cover-
age values falling within each of the above coverage
strata (5-24%, 25-44%, 45-64% and 65-84%).
Step 2: Estimation of the number of true prevalent cases
We next inputted into the model, for each screening ses-
sion, the project-specific ρ estimates derived above,
sampled from their uncertainty distribution; the actual
values of N, c and diagnostic accuracy specific to the
session; and candidate sets of S1 and S2 values (from 0
to N). For each screening session, we evaluated each set
of S1 and S2 values over 10 000 iterations, by computing
how frequently the set of values yielded perfect predic-
tions of observed prevalence, i.e.
S1;obs;pred ¼ S1;obs;data AND S2;obs;pred ¼ S2;obs;data
For each iteration that yielded a perfect fit, we also
recorded the predicted true cases detected S1,TP,pred and
S2,TP,pred if they did not exceed the total cases observed
S1;TP;pred≤S1;obs;pred AND S2;TP;pred≤S2;obs;pred
 
, and those
among these that were classified in the correct stage
(S1, TP,pred – S1,TP,mis,pred and S2,TP,pred – S2,TP,mis,pred).
The set of S1 and S2 most frequently fitting the data was
adopted as the best estimate for that screening session.
95% confidence intervals were computed by the method
of profiles applied to a two-dimensional joint likelihood
distribution [20].
Best estimates and uncertainty bounds for each project
as a whole were computed by two alternative analysis
approaches: (i) summing the best-fitting values of of S1
and S2 or S1,TP and S2,TP for each screening session over
the project as a whole (no uncertainty bounds could be
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computed for this approach); and (ii) a bootstrapping
routine, whereby we repeatedly sampled from the joint
likelihood distributions of S1 and S2 or S1,TP and S2,TP
for each screening session, totalled the randomly
sampled values over all sessions in the project, and com-
puted the median and 95% percentile interval of the
resulting distribution of random project totals.
STP/S is the detected fraction. We could not find a
straightforward way to compute uncertainty bounds
around this estimate, as it includes error from several
sources arising from different statistical processes. How-
ever, we present alternative best estimates of detected
fraction using either of the above estimation approaches.
Results
Description of mass screening data
Screening output
Altogether, 819 mass screening sessions took place in
the three projects over the periods covered by the data-
sets used in this study. However, population data were
missing for 203 sessions; 10 yielded zero prevalence in
villages that also reported no cases throughout the pro-
ject duration; and two had a coverage <5% and were
assumed to be data entry errors. This left 604 sessions
for the present analysis, performed in 246 villages
(Table 3).
Screening coverage was highest in Kiri, where about
half of screening sessions reported a coverage > 100%,
suggesting people from neighbouring communities may
have attended (Table 3). Overall, 714 898 people were
targeted for screening (with 472 015 actually screened):
56 590 (49 551) in Kiri, 300 406 (158 954) in Adjumani,
and 364 902 (263 510) in Arua-Yumbe. Cases diagnosed
were 221 (114 in stage 1 or 51.6%) in Kiri, 1419 (692,
48.8%) in Adjumani, and 570 (327, 57.4%) in Arua-Yumbe.
Exploration of factors associated with observed prevalence
A hurdle model of factors associated with observed
prevalence combining data from all projects (Table 4)
suggested weak evidence of a trend in the association
between screening coverage and occurrence of non-zero
prevalence (log-log component): sessions with coverage
<15% were about one third as likely to yield any HAT
cases than sessions with coverage around 100%. The
probability of non-zero prevalence also increased with
village population size and previous observed incidence
rate, but was lower in repeat screening rounds.
Among screenings that yielded non-zero prevalence
(negative binomial component), there was also evidence
of a trend in the association of screening coverage and
prevalence, with βc increasing as a function of decreas-
ing coverage, as hypothesized. Prevalence increased with
previous incidence, but repeat screening rounds were
associated with lower prevalence. Unlike in the log-log
component, prevalence decreased with increasing popu-
lation size (see Discussion). There was no evidence of
interactions in either model component (data not
shown).
Estimates of the detected fraction
Estimated relative risk ρ of attending screening
Table 5 shows adjusted estimates of βc based on a hurdle
model of field data for each project, used in further steps
of the analysis to βc. The fit of estimated ρ values was
Table 3 Screening coverage of screening sessions included in the analysis, by project
Coverage stratum (%) Kiri, Sudan
(n = 142)
Adjumani, Uganda
(n = 320)
Arua-Yumbe,
Uganda (n = 142)
5-14 1 (0.7) 13 (4.1) 2 (1.4)
15-24 9 (6.3) 26 (8.1) 3 (2.1)
25-34 5 (3.5) 34 (10.6) 5 (3.5)
35-44 13 (9.2) 38 (11.9) 14 (9.9)
45-54 9 (6.3) 49 (15.3) 16 (11.3)
55-64 7 (4.9) 42 (13.1) 15 (10.6)
65-74 8 (5.6) 40 (12.5) 18 (12.7)
75-84 6 (4.2) 38 (11.9) 22 (15.5)
85-94 7 (4.9) 14 (4.4) 23 (16.2)
95-104 4 (2.8) 12 (3.8) 6 (4.2)
105-199 31 (21.8) 12 (3.8) 16 (11.3)
≥200 42 (29.6) 2 (0.6) 2 (1.4)
Mean coverage% (IQR†) 192.9 (51.7-231.0) 58.7 (37.4-74.0) 75.3 (52.5-89.5)
Mean coverage% (IQR†) considering
any coverage> 100% as = 100%
77.9 (52.4-100.0) 55.8 (37.6-73.9) 70.6 (52.7-89.3)
†Inter-quartile range.
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good (Figure 2). The best estimates of ρ were 1.6 (95%CI
0.7-12.8) for Kiri, 2.5 (1.2-36.6) for Adjumani and 1.9
(0.9-4.0) for Arua-Yumbe, suggesting a consistent pat-
tern across sites. These ρ estimates yielded βc values
that provided a good fit to the βc values estimated from
field data.
Estimated true prevalence and detected fraction
The estimated true prevalence using the best-fitting
estimates from each session (approach i) was very
similar to that observed (Table 6). True prevalence using
bootstrapping estimates (approach ii) was almost equal
to that observed in Adjumani and Arua-Yumbe, but was
about double the observed in Kiri, though still below 1%
in absolute terms; the proportion of stage 1 cases was
estimated to be higher in reality than that observed, as
expected due to the adjustment for stage misclassification,
and the fact that most false positives would have been
diagnosed as stage 2 (Table 6): observed stage-specific
prevalence differed from the true prevalence accordingly.
Table 4 Hurdle model exploring factors associated with observed HAT prevalence (all projects combined)
Variable Number of observations
(number with non-zero
prevalence)
Log-log component: probability
of non-zero prevalence
Negative-binomial component: prevalence
conditional on prevalence being non-zero
Probability
ratio (adjusted)
95%CI Prevalence
ratio (adjusted)
95%CI
Screening coverage (%)
5-14 16 (5) 0.28† 0.09-0.89 3.39† βc 1.25-9.21
15-24 38 (19) 0.52 0.25-1.09 2.83 1.58-5.04
25-34 44 (31) 0.78 0.37-1.63 1.77 0.95-3.27
35-44 65 (37) 0.64 0.32-1.28 1.49 0.79-2.81
45-54 74 (46) 0.74 0.37-1.49 1.49 0.85-2.64
55-64 64 (46) 1.18 0.60-2.35 1.47 0.78-2.76
65-74 66 (47) 1.08 0.54-2.17 1.25 0.70-2.24
75-84 66 (46) 0.89 0.44-1.82 1.12 0.62-2.03
85-94 44 (27) 0.79 0.37-1.66 1.19 0.61-2.35
95-104 22 (16) 1 [reference] 1 [reference]
105-199 59 (33) 0.95 0.45-2.00 0.69 0.36-1.32
≥200 46 (25) 1.61 0.65-3.99 0.34 0.15-0.78
Screening round
first round 246 (176) 1 [reference] 1 [reference]
subsequent rounds 358 (202) 0.56 0.44-0.71 0.58 0.47-0.72
Village population size
<100 38 (12) 1† [reference] 1† [reference]
100-499 141 (71) 1.98 0.91-4.26 0.50 0.26-0.94
500-999 166 (111) 3.07 1.31-7.20 0.34 0.16-0.71
≥1000 259 (184) 3.84 1.60-9.19 0.23 0.11-0.49
Observed incidence rate in the past 6 months (cases per 1000 person-months)
0.00 239 (100) 1 [reference] 1† [reference]
0.01-0.99 263 (201) 2.38 1.80-3.15 1.45 1.20-1.77
1.00-4.99 86 (63) 3.04 2.11-4.37 3.40 2.47-4.68
≥5.00 16 (14) 6.08 3.15-11.73 6.16 3.84-9.87
Project
Adjumani 320 (215) 1 [reference] 1 [reference]
Arua-Yumbe 142 (104) 0.77 0.54-1.10 0.40 0.27-0.59
Kiri 142 (59) 0.65 0.41-1.05 1.02 0.70-1.48
p (goodness of fit): <0.0001 p (goodness of fit): <0.0001
† Test for trend p< 0.001.
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Overall, the estimated detected fraction was relatively
high everywhere using analysis approach i, i.e. taking the
best-fitting estimates from each screening session (84.0%
[221/263] in Kiri, 79.9% [1419/1777] in Adjumani and
88.0% [570/648] in Arua-Yumbe), but much lower
(42.2% [214/507] in Kiri, 52.5% [1375/2618] in Adjumani
and 59.3% [527/888] in Arua-Yumbe) using approach ii,
i.e. taking median estimates from bootstrapping (see Dis-
cussion). When considering only cases detected and cor-
rectly staged, these percentages declined to 68.1% (179/
263), 60.4% (1074/1777) and 61.9% (401/648) for
approach i, and 33.1% (168/507), 39.9% (1045/2617) and
47.4% (421/888) for approach ii.
Discussion
This study outlines a potential method to estimate the
extent of under-detection and the true infection burden
of gambiense HAT, based only on observed data. Be-
cause of the extent of uncertainty as regards model
parameters, estimates of detected fraction are quite
imprecise, but suggest that between 20-50% of prevalent
cases were not detected in the screening sessions
Table 5 Adjusted estimates of βc (ratio of observed prevalence at coverage c to observed prevalence at
coverage =100%) for each project, by screening coverage stratum
Project Screening coverage stratum (%)
5-24 25-44 45-64 65-84 85-115 (ref.)
n† βc n βc n βc n βc n βc
Kiri 10 1.64 (0.57-4.70) 18 1.35 (0.63-2.90) 16 1.35 (0.50-3.62) 14 1.22 (0.64-2.35) 17 1 [ref.]
Adjumani 39 2.76 (1.72-4.43) 72 1.50 (0.93-2.41) 91 1.41 (0.93-2.13) 78 1.05 (0.67-1.66) 29 1 [ref.]
Arua-Yumbe 5 1.81 (1.28-2.55) 19 1.25 (0.63-2.49) 31 1.47 (1.12-1.93) 40 1.02 (0.73-1.43) 34 1 [ref.]
†Number in category.
Quantities in parentheses indicate 95% confidence intervals.
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Figure 2 Predicted versus observed βc (ratio of observed prevalence at coverage c to observed prevalence at coverage= 100%) values,
by project, using the best estimate of ρ (relative probability of attending screening among cases versus non-cases). Vertical bars
indicate 95% confidence intervals.
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analysed. There appears to be no appreciable difference
between observed and true prevalence. However, adjust-
ment for incomplete specificity and stage misclassifica-
tion suggests a higher ratio of stage 1 to stage 2 than
that observed by programmes.
Interpretation of findings
Internal validity of findings
The hurdle model is internally consistent: with the excep-
tion of population size (see below), associations of explana-
tory variables and prevalence in the log-log component
are mirrored in the negative-binomial component.
Furthermore, the log-log component supports the
hypothesis of ρ > 1. If ρ= 1, the probability of a village
featuring a non-zero observed prevalence should be
linearly proportional to screening coverage. However,
this probability is higher than expected based on cover-
age alone, consistent with self-selection of cases even at
low coverage.
While increasing village population size was associated
with a higher probability of non-zero prevalence, preva-
lence among non-zero screenings appeared to decrease
with higher population. This apparently inconsistent
finding may be explained as follows: (i) in fact, the prob-
ability of non-zero prevalence increases less than pro-
portionately with increasing population size, meaning
that, on a per capita basis, it is lower in large villages
than small ones; (ii) in smaller communities, there may
be a greater risk of chance extinction of transmission,
and thus a greater frequency of zero prevalence, all else
being equal; (iii) if cases are present in a small village,
their very small number, not divisible below discrete
units, affects the prevalence calculation (e.g. if two
villages A and B both have one prevalent case, but A’s
population is 100 and B’s 1000, the prevalence will be
ten times higher in A); (iv) larger communities are usu-
ally administrative and economic centres, and attract
infected migrants from rural areas; (v) village population
size may not reflect the actual denominator at risk: it is
likely that only a fraction of the population has a
livelihood-dependent exposure to tsetse [21,22], and that
this fraction may be smaller in larger, less rural com-
munities where many people are engaged in trade or
services: in other words, when considering the true
population at risk, denominators might be more com-
parable across differently sized villages than it appears.
Under-detection
Overall, this study estimates that about 20-50% of preva-
lent cases potentially detectable fell through the net of
active case detection, and that about a fourth of cases
detected were not classified in the correct stage (how-
ever, most misclassification would be from stage 1 to
stage 2, which would still guarantee effective treatment).
Our model did not incorporate the final step of treat-
ment, as our question concerned case detection specific-
ally; furthermore, the MSF projects used a variety of
regimens, including second-line regimens for patients
with treatment failure. In national programmes without
strong funding and technical support, screening cover-
age could be lower, and our findings thus reflect an opti-
mistic scenario. In the Democratic Republic of Congo
(DRC), the estimated detected fraction (including treat-
ment) was <50% in most scenarios, and between 30%
and 65% attended and were correctly diagnosed [23].
Screening coverage was 22-98% in other DRC sites
Table 6 Estimated true number of cases and prevalence, by stage, project and overall
Project Estimated number of cases (95% confidence interval) Prevalence in% (95% confidence interval)
Observed True cases among observed True cases overall Observed† True{
Kiri
stage 1 114 135, 143 (127–158) 177, 315 (255–388) 0.23 0.31, 0.56 (0.45-0.69)
stage 2 107 86, 71 (55–86) 86, 189 (145–257) 0.22 0.15, 0.33 (0.26-0.45)
Total 221 221, 214 (207–219) 263, 507 (429–608) 0.45 0.46, 0.90 (0.76-1.07)
Adjumani
stage 1 692 868, 913 (863–963) 1129, 1628 (1485–1775) 0.44 0.38, 0.54 (0.49-0.59)
stage 2 727 551, 463 (410–513) 648, 993 (872–1128) 0.46 0.22, 0.33 (0.29-0.38)
Total 1419 1419, 1375 (1360–1389) 1777, 2618 (2436–2811) 0.90 0.59, 0.87 (0.81-0.94)
Arua-Yumbe
stage 1 327 404, 392 (366–417) 495, 624 (564–693) 0.12 0.14, 0.17 (0.15-0.19)
stage 2 243 166, 135 (109–162) 153, 262 (214–321) 0.09 0.04, 0.07 (0.06-0.09)
Total 570 570, 527 (510–540) 648, 888 (816–974) 0.21 0.18, 0.24 (0.22-0.27)
†Observed cases divided by the total population actually screened. {Estimated cases divided by the total population targeted for screening.
Estimated figures indicate, respectively, sum of best-fitting values for each screening session, median of bootstrapping replicate samples (95% percentile of
bootstrapping samples).
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(average 70-80%) [7,23], 47-93% in Equatorial Guinea
[24], and 70-94% in Angola [25].
In the colonial era, HAT active case detection was
successful due to largely coercive measures. Few recent
studies discussing the barriers to and facilitators of
screening attendance have been published. In the Repub-
lic of Congo, villagers reported that biomedical medicine
was the main remedy against HAT, and did not trust
traditional remedies [26]. In the DRC, communities’
knowledge of HAT and its control was very good, but
concern with drug toxicity and the stigma of public
HAT diagnosis were prominent barriers [27]. Both stud-
ies found that cost of treatment was a barrier to service
uptake; while MSF projects offered free testing and
treatment, patients and families face transport costs,
income lost, etc. In both Congo [28] and DRC, stage 2
HAT was often associated with sorcery, especially when
the case was fatal: however, there was no evidence that
this kept patients from seeking care. In the Ugandan
sites we analysed, traditional healers were often a
recourse, and working with these providers and com-
munities was suggested as a way to improve screening
attendance [29].
Other findings
In communities where a non-zero incidence was
observed in the six months prior to the mass screening,
there was a doubled probability of finding at least one
case during active screening. Furthermore, past inci-
dence was associated with observed prevalence.
There was no evidence that cases in stage 2 have a
greater probability of attending mass screening than
those in stage 1. This observation is somewhat unex-
pected: stage 2 cases, being more symptomatic, might be
expected to have a greater probability of attending
screenings. This finding, however, may not apply to pas-
sive case detection. Furthermore, early stage 2 cases may
in fact be less prone to present with systemic symptoms
like fever, pruritus or arthralgia than stage 1 cases [30].
Programmatic implications
While the uncertainty around the estimates of detected
fraction (see below) hampers meaningful interpretation,
it is clear that a considerable proportion of HAT infec-
tions remain undetected even in a well-resourced active
case finding context. These cases would then go on to
seed renewed epidemics once mass screening is scaled
down, and, where no passive case detection is available,
would probably die. Long-term control of HAT through
mass screening thus probably requires very high screen-
ing coverage, underscoring the need for programmes to
work closely with communities to ensure high accept-
ance and uptake and identify and address barriers to
screening attendance. This is also justifiable from an
economic standpoint, given that the costs of mass
screening are mainly fixed (e.g. transport, human
resources, information campaigns, programme over-
heads) rather than variable (i.e. per person screened).
This study suggests that, for purposes of assessing
HAT burden and monitoring trends, calculating the
observed prevalence based on detected cases and the
number of people screened provides a reasonable
approximation to the true prevalence. Furthermore,
programmes should continue to use the observed inci-
dence in different communities (as computed based on
passive case detection, where available) as a guide for
deciding where to focus mass screening efforts.
Study limitations
Estimates were subject to considerable uncertainty,
which hampers interpretation of the key findings on
detected fraction. The striking differences according to
analysis approach are due to the very skewed likelihood
distributions arising from the fitting procedures (data
not shown): reporting the mode (best-fitting values) or
median of these distributions changes the inference con-
siderably. For completeness, we have chosen to report
both, and suggest that reality lies somewhere in between.
Furthermore, the model does not adequately deal with
screening sessions featuring zero observed prevalence
(37% of sessions analysed). If screening coverage is <
100%, various possible sets of S1 and S2 values could
result in S1,obs = 0 and S2,obs = 0; in most scenarios, how-
ever, the set [S1 = 0, S2 = 0], i.e. zero prevalence, will by
default yield the best fits and will thus be adopted as the
best estimate, potentially resulting in a systematic under-
estimation of true prevalence in very low transmission
villages (and overestimation of the detected fraction) if
analysis approach i is used. Approach ii is less affected
by this bias.
For screening sessions with coverage > 100%, the
model relies on an assumption that the entire population
of the village was screened, and that any other persons
screened come from neighbouring villages. While this
occurred rarely in Adjumani and Arua-Yumbe, in Kiri
about half of screening sessions attracted a population
greater than that of the village; results for Kiri should
thus be considered somewhat less robust.
The association between coverage and observed preva-
lence was adjusted for all available confounding vari-
ables, but these (screening round, population size,
project, past incidence) were few, and additional hidden
confounding may be present: villages with low coverage
may differ systematically from high-coverage ones in
other key determinants of prevalence, such as expo-
sure to vectors; low coverage might also be a proxy for
remoteness and low security, which could be associated
with higher prevalence.
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Conclusions
The fraction of HAT cases detected during active screen-
ing may be relatively high in well-resourced control pro-
grammes, providing a considerable immediate public
health benefit. However, the minority of cases that
remain undetected may play a critical epidemiological
role in sustaining transmission.
The limitations of this study illustrate multiple difficul-
ties in estimating the unseen burden of neglected trop-
ical diseases in settings with low access to health care
and limited availability of data. Our modelling approach
may be useful for improved HAT burden estimation and
programme evaluation, but needs to be improved.
Determinants of under-detection should also be
researched further using both quantitative and qualita-
tive tools, so as to maximise the future impact of this
control strategy.
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